Board Approves Final dividend for the FY 2024-25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Sandu Pharmaceuticals has recommended a final dividend of Rs. 0.80 per equity share, which works out to 8% on the paid-up face value of Rs. 10 per share, for the financial year ended March 31, 2025. This recommendation is subject to approval by shareholders at the upcoming Annual General Meeting. The company has stated that the AGM date, record date (cut-off for eligibility), and actual dividend payment date will be communicated separately. The decision was taken at a board meeting held on May 28, 2025, and follows an earlier intimation dated May 17, 2025.
This is a modest dividend payout, reflecting steady but conservative cash returns to shareholders. Investors holding shares on the record date will receive Rs. 0.80 per share. The attractiveness of this dividend depends on the current market price of the stock — the actual yield percentage cannot be determined from this filing alone.